{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:19:24Z","timestamp":1790936364977,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,1,22]],"date-time":"2004-01-22T00:00:00Z","timestamp":1074729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,1,22]],"date-time":"2004-01-22T00:00:00Z","timestamp":1074729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2004,3,1]]},"DOI":"10.1038\/sj.leu.2403258","type":"journal-article","created":{"date-parts":[[2004,1,29]],"date-time":"2004-01-29T10:38:06Z","timestamp":1075372686000},"page":"484-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia"],"prefix":"10.1038","volume":"18","author":[{"given":"J","family":"Lundin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Porwit-MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E D","family":"Rossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Edman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Rezvany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Mellstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,1,22]]},"reference":[{"key":"BF2403258_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","volume":"347","author":"S Johnson","year":"1996","unstructured":"Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432\u20131438.","journal-title":"Lancet"},{"key":"BF2403258_CR2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia. N Engl J Med 2000; 343: 1750\u20131757.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"BF2403258_CR3","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1385\/MO:19:2S:S11","volume":"19","author":"E Montserrat","year":"2002","unstructured":"Montserrat E . Current and developing chemotherapy for CLL. Med Oncol 2002; 19 (Suppl): S11\u2013S19.","journal-title":"Med Oncol"},{"key":"BF2403258_CR4","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","volume":"20","author":"KR Rai","year":"2002","unstructured":"Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA et al. Alemtuzumab in previously treated chronic lymphocytic leukaemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891\u20133897.","journal-title":"J Clin Oncol"},{"key":"BF2403258_CR5","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554\u20133561.","journal-title":"Blood"},{"key":"BF2403258_CR6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukaemia. J Clin Oncol 1997; 15: 1567\u20131574.","journal-title":"J Clin Oncol"},{"key":"BF2403258_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","volume":"93","author":"A Osterborg","year":"1996","unstructured":"Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H . Humanized CD52 monoclonal antibody CAMPATH-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93: 151\u2013153.","journal-title":"Br J Haematol"},{"key":"BF2403258_CR8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","volume":"82","author":"MH Gilleece","year":"1993","unstructured":"Gilleece MH, Dexter TM . Effect of CAMPATH-1H antibody on human haematopoietic progenitors in vitro. Blood 1993; 82: 807\u2013812.","journal-title":"Blood"},{"key":"BF2403258_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (CAMPATH-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (B-CLL). Blood 2002; 100: 768\u2013773.","journal-title":"Blood"},{"key":"BF2403258_CR10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood.V86.4.1487.bloodjournal8641487","volume":"86","author":"B Hertenstein","year":"1995","unstructured":"Hertenstein B, Wagner B, Bunjes D, Duncker C, Raghavachar A, Arnold R et al. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of CAMPATH-1H for refractory B-cell non-Hodgkin lymphoma. Blood 1995; 86: 1487\u20131492.","journal-title":"Blood"},{"key":"BF2403258_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1046\/j.1365-2141.1999.01676.x","volume":"107","author":"AC Rawstron","year":"1999","unstructured":"Rawstron AC, Rollinson SJ, Richards S, Short MA, English A, Morgan GJ et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol 1999; 107: 148\u2013153.","journal-title":"Br J Haematol"},{"key":"BF2403258_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-0609.1997.tb01403.x","volume":"58","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H et al. Clonal CD8+ and CD52\u2212 T cells are induced in responding B cell lymphoma patients treated with CAMPATH-1H (anti-CD52). Eur J Haematol 1997; 58: 5\u201313.","journal-title":"Eur J Haematol"},{"key":"BF2403258_CR13","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990\u20134997.","journal-title":"Blood"},{"key":"BF2403258_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS . Clinical staging of chronic lymphocytic leukaemia. Blood 1975; 46: 219\u2013234.","journal-title":"Blood"},{"key":"BF2403258_CR15","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","volume":"16","author":"J Lundin","year":"1998","unstructured":"Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16: 3257\u20133263.","journal-title":"J Clin Oncol"},{"key":"BF2403258_CR16","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/cncr.0680","volume":"94","author":"JG Perkins","year":"2002","unstructured":"Perkins JG, Flynn JM, Howard RS, Byrd JC . Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94: 2033\u20132039.","journal-title":"Cancer"},{"key":"BF2403258_CR17","first-page":"331","volume":"30","author":"F Vuillier","year":"1988","unstructured":"Vuillier F, Tortevoye P, Binet JL, Dighiero G . CD4, CD8 and NK subsets in B-CLL. Nouv Rev Fr Hematol 1988; 30: 331\u2013334.","journal-title":"Nouv Rev Fr Hematol"},{"key":"BF2403258_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/(SICI)1096-8652(199707)55:4<175::AID-AJH2>3.0.CO;2-P","volume":"55","author":"E Reyes","year":"1997","unstructured":"Reyes E, Prieto A, Carrion F, Garcia-Suarez J, Esquivel F, Alvarez-Mon M . Morphological variants of leukemic cells in B chronic lymphocytic leukaemia are associated with different T cell and NK cell abnormalities. Am J Hematol 1997; 55: 175\u2013182.","journal-title":"Am J Hematol"},{"key":"BF2403258_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1046\/j.1365-2567.1996.d01-650.x","volume":"88","author":"S Brett","year":"1996","unstructured":"Brett S, Baxter G, Cooper H, Johnston JM, Tite J, Rapson N . Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996; 88: 13\u201319.","journal-title":"Immunology"},{"key":"BF2403258_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1097\/00007890-200004150-00022","volume":"69","author":"GM Davison","year":"2000","unstructured":"Davison GM, Novitzky N, Kline A, Thomas V, Abrahams L, Hale G et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 1341\u20131347.","journal-title":"Transplantation"},{"key":"BF2403258_CR21","first-page":"142","volume":"67","author":"A Parreira","year":"1987","unstructured":"Parreira A, Smith J, Hows JM, Smithers SA, Apperley J, Rombos Y et al. Immunological reconstitution after bone marrow transplant with CAMPATH-1 treated bone marrow. Clin Exp Immunol 1987; 67: 142\u2013150.","journal-title":"Clin Exp Immunol"},{"key":"BF2403258_CR22","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","volume":"99","author":"S Chakrabarti","year":"2002","unstructured":"Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of CAMPATH-1H in delaying immune reconstitution. Blood 2002; 99: 4357\u20134363.","journal-title":"Blood"},{"key":"BF2403258_CR23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/0140-6736(92)92294-P","volume":"340","author":"JD Isaacs","year":"1992","unstructured":"Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748\u2013752.","journal-title":"Lancet"},{"key":"BF2403258_CR24","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691\u20131695.","journal-title":"Lancet"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403258","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:39:19Z","timestamp":1648777159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,22]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3,1]]}},"alternative-id":["BF2403258"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403258","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,22]]},"assertion":[{"value":"27 June 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}